Company Profile

Epicentre Technologies Corporation (AKA: Epicentre Biotechnologies)
Profile last edited on: 11/13/2023      CAGE: 03WG6      UEI: ----------

Business Identifier: Biological Products, Except Diagnostic
Year Founded
1987
First Award
1990
Latest Award
2021
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5602 Research Park Boulevard Suite 200
Madison, WI 53719
   (608) 258-3080
   techhelp@epicentre.com
   www.epibio.com
Location: Single
Congr. District: 02
County: Dane

Public Profile

Epicentre(R) Biotechnologies, founded in 1987, uses its expertise in enzyme manufacturing to produce innovative kits for life science research. The kits and reagents manufactured by Epicentre contribute to breakthrough studies in genomics and transcriptomics. Products are available for DNA and RNA sequencing, gene expression analysis, DNA and RNA purification, PCR and RT-PCR, cloning, in vitro transcription, and microbial genomics. Epicentre's products are used worldwide in academic, commercial, and government laboratories in diverse applications, including basic research, drug discovery, cancer research, infectious disease research, microbiology, and personalized medicine. On January 10, 2011, Epicentre was acquired by Illumina, Inc. The company continues to operate as a wholly owned subsidiary of Illumina from its headquarters in Madison, Wisconsin.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 2 DOE $1,349,962
Project Title: Advanced Laser Ultrasonic Sensor for Fuel Rod Characterization
2000 1 NIH $100,000
Project Title: An RNA Polymerase for Synthesis of Capped RNAs
2000 1 DOE $100,000
Project Title: Rapid, Direct Sequencing of Bacterial Artificial Chromosome Clones Using Transposomes-tm
1990 1 NIH $50,000
Project Title: Characterization of the potential new antimicrobial agent

Key People / Management

  Gary Dahl -- President

  Linda A Guarino

  Jerome Jendrisak

  Marvin B Klein

Company News

There are no news available.